A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
暂无分享,去创建一个
R. Mohs | R. Doody | M. Farlow | L. Friedhoff | S. L. Rogers | M. R. Farlow | R. S. Doody | R. Mohs | L. T. Friedhoff | M. Farlow | S. Rogers
[1] G. Reynolds. Banbury Report 15, Biological Aspects of Alzheimer's Disease: edited by R. Katzman, Cold Spring Harbor Laboratory, 1983. US $55.00 ($66.00 outside US) (xiv + 495 pages) ISBN 0 87969 213 8 , 1984 .
[2] Gastone G. Celesia,et al. A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .
[3] E. Giacobini,et al. Cholinergic Basis for Alzheimer Therapy , 1991, Advances in Alzheimer Disease Therapy.
[4] L. Friedhoff,et al. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial , 1996 .
[5] L. Schneider,et al. Predicting Response to Cholinesterase Inhibitors in Alzheimer’s Disease , 1995 .
[6] A. Thomas,et al. Genesis and evolution of behavioral disorders: from infancy to early adult life. , 1984, The American journal of psychiatry.
[7] T. H. Blau. Quality of life, social indicators, and criteria of change. , 1977 .
[8] L. Thal,et al. Memory improvement with oral physostigmine and lecithin in alzheimers disease , 1983 .
[9] P. Davies,et al. SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.
[10] K. Davis,et al. Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report. , 1988, Psychopharmacology bulletin.
[11] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[12] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[13] M Farlow,et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.
[14] R. Elble,et al. Effects of metrifonate, a long‐acting cholinesterease inhibitor, in alzheimer disease: Report of an open trial , 1990 .
[15] A W Toga,et al. Sulcal variability in the Alzheimer's brain , 1998, Neurology.
[16] Y. Yamanishi,et al. E2020 - THE PHARMACOLOGY OF A PIPERIDINE CHOLINESTERASE INHIBITOR , 1991 .
[17] J. Coyle,et al. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.
[18] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[19] J. Baty,et al. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention , 1992, Annals of neurology.
[20] M. Crismon,et al. Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease: A Double-blind, Placebo-Controlled Study , 1995 .
[21] K. Davis,et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.
[22] E. Giacobini,et al. Present progress and future development in the therapy for Alzheimer's disease. , 1989, Progress in clinical and biological research.
[23] P. Antuono. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group. , 1995, Archives of internal medicine.
[24] S H Ferris,et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.
[25] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[26] R. Terry,et al. Senile dementia of the Alzheimer type , 1983, Annals of neurology.
[27] Prien Rf. Methods and models for placebo use in pharmacotherapeutic trials. , 1988 .
[28] D. Knopman,et al. Observations on the short‐term 'natural history' of probable Alzheimer's disease in a controlled clinical trial , 1994, Neurology.
[29] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[30] J. Morris,et al. Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) , 1997 .
[31] R. Hayward,et al. INTRACEREBRAL HÆMORRHAGE Accuracy of Computerised Transverse Axial Scanning in Predicting the Underlying Aetiology , 1976, The Lancet.
[32] G. Blessed,et al. NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.
[33] Clinical trials with velnacrine: (PROPP) The physician reference of predicted probabilities—A statistical model for the estimation of hepatotoxicity risk with velnacrine maleate , 1993, Acta neurologica Scandinavica. Supplementum.
[34] A. Burns. Clinical diagnosis of Alzheimer's disease , 1991 .
[35] M. Tsuang. Genetics, epidemiology, and the search for causes of schizophrenia. , 1994, The American journal of psychiatry.
[36] J. Morris,et al. Validity and Reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change , 2017 .
[37] K. Davis,et al. Oral physostigmine treatment of patients with Alzheimer's disease. , 1985, The American journal of psychiatry.
[38] R. Becker,et al. The Second Generation of Cholinesterase Inhibitors: Clinical and Pharmacological Effects , 1991 .